InicioPTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Cierre anterior
15,89 $
Intervalo anual
11,44 $ - 23,73 $
Cap. bursátil
55,01 B IDR
Volumen medio
35,00
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (IDR) | jun 2025info | Cambio interanual |
|---|---|---|
Ingresos | 8,23 B | 3,37 % |
Gastos operativos | 2,24 B | 10,65 % |
Ingresos netos | 898,17 mil M | 5,97 % |
Margen de beneficio neto | 10,91 | 2,54 % |
Beneficios por acción | 19,78 | 8,50 % |
EBITDA | 1,26 B | 0,42 % |
Tipo impositivo efectivo | 23,09 % | — |
Balance general
Activos totales
Responsabilidades totales
| (IDR) | jun 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 3,95 B | 2,69 % |
Activos totales | 29,51 B | 3,30 % |
Responsabilidades totales | 5,32 B | 5,83 % |
Patrimonio total | 24,19 B | — |
Acciones en circulación | 45,39 mil M | — |
Precio-valor contable | 0,03 | — |
Rentabilidad económica | 8,82 % | — |
Retorno sobre capital | 10,42 % | — |
Flujo de caja
Variación neta del flujo de caja
| (IDR) | jun 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | 898,17 mil M | 5,97 % |
Efectivo de operaciones | 956,75 mil M | -17,88 % |
Efectivo de inversión | 117,04 mil M | 123,27 % |
Efectivo de financiación | -1,78 B | -47,25 % |
Variación neta del flujo de caja | -740,01 mil M | -90,86 % |
Flujo de caja libre | 667,76 mil M | 18,23 % |
Información sobre la empresa
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Fundación
10 sept 1966
Sitio web
Empleados
12.832
